Overview

Afatinib Plus Nimotuzumb for NSCLC

Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to gefitinib or erlotinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Afatinib
Nimotuzumab